Rosen Law Firm Urges AstraZeneca Investors to Act Before February Deadline

NEW YORK, Feb. 09, 2025 (GLOBE NEWSWIRE) --

WHY: The Rosen Law Firm, an internationally recognized law firm focused on protecting investor rights, is reminding individuals who purchased securities of AstraZeneca PLC (NASDAQ: AZN) from February 23, 2022, to December 17, 2024 (the "Class Period"), of the important deadline of February 21, 2025, to secure lead plaintiff status in a securities class action lawsuit initiated by the firm.

SO WHAT: Investors who bought AstraZeneca shares during the specified Class Period may be eligible to seek compensation for their losses. Importantly, there are no upfront costs associated with this process due to a contingency fee arrangement, meaning that legal fees are only payable if the case is successful.

WHAT TO DO NEXT: To take part in the AstraZeneca class action or to learn more about your options, visit this link, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected]. A lawsuit has already been initiated, and those interested in becoming a lead plaintiff must file with the court by February 21, 2025. The lead plaintiff plays a crucial role, representing the interests of all affected investors in the case.

WHY ROSEN LAW: It is advisable for investors to choose legal representation from firms with proven success in such cases. Many firms that send out notices do not have significant experience or recognition in litigating securities class actions. In fact, numerous firms merely act as intermediaries, referring clients to other attorneys. The Rosen Law Firm focuses on investor protection through financial litigation, having achieved notable settlements and recognitions in the field. In 2017, the firm was ranked number one by ISS Securities Class Action Services for settlements achieved and has consistently ranked in the top positions over the years. The firm has recovered hundreds of millions for its clients, including over $438 million in 2019 alone. Laurence Rosen, the founding partner, was named a Titan of the Plaintiffs' Bar by Law360 in 2020, reflecting the firm’s expertise and success in defending investor rights.

DETAILS OF THE CASE: The securities class action alleges that throughout the Class Period, AstraZeneca and its executives made misleading statements and failed to disclose important information regarding the company's operations. Specific allegations include that AstraZeneca engaged in illegal practices related to insurance in China, leading to increased legal risks and the eventual detention of AstraZeneca's China President. The lawsuit claims that false information presented by the defendants resulted in significant harm to investors once the truth was revealed.

To join the AstraZeneca class action, visit this link, call Phillip Kim, Esq. toll-free at 866-767-3653, or email [email protected] for further details.

IMPORTANT NOTE: No class has been certified yet. Until a class is officially formed, you will not be represented unless you retain your own legal counsel. You have the option to select your preferred legal representation or to remain an uninvolved member of the class for now. Participating as a lead plaintiff is not a requirement for being eligible for any future financial recovery from this case.

Stay updated by following us on LinkedIn: LinkedIn or on Twitter: Twitter.

Attorney Advertising: Past outcomes do not guarantee similar results.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40^th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

AstraZeneca, lawsuit, investment